NO供体型苦参碱衍生物的合成及抗肿瘤活性

高等学校化学学报 ›› 2010, Vol. 31 ›› Issue (8): 1541.

NO供体型苦参碱衍生物的合成及抗肿瘤活性

何黎琴^1,2, 顾宏霞², 尹登科², 张奕华¹, 王效山²

1. 中国药科大学新药研究中心, 南京 210009;
2. 安徽中医学院, 安徽省现代中药重点实验室, 合肥 230031

收稿日期:2009-12-31 出版日期:2010-08-10 发布日期:2010-08-10
通讯作者: 张奕华, 男, 教授, 博士生导师, 从事药物化学方面研究. E-mail: zyhtgd@sohu.com
基金资助:
安徽省教育厅自然科学重点科研项目(批准号： KJ2010A204)资助.

Synthesis and Anti-cancer Activity of Nitric Oxide Donor-based Matrine Derivatives

HE Li-Qin^1,2, GU Hong-Xia², YIN Deng-Ke², ZHANG Yi-Hua^1*, WANG Xiao-Shan²

1. Center of Drug Discovery, China Pharmaceutical University, Nanjing 210009, China;
2. Key Laboratory of Modernized Chinese Material Medical of Anhui Province, Anhui College of Traditional Chinese Medicine, Hefei 230031, China

Received:2009-12-31 Online:2010-08-10 Published:2010-08-10
Contact: ZHANG Yi-Hua. E-mail: zyhtgd@sohu.com
Supported by:
安徽省教育厅自然科学重点科研项目(批准号： KJ2010A204)资助.

摘要/Abstract

摘要： 以苦参碱为原料, 设计合成了13个NO供体型苦参碱衍生物, 衍生物的结构经EI-MS, ¹H NMR, IR和元素分析确证. 采用 MTT法测试所合成化合物的体外抗肿瘤活性, 结果表明, 所合成的化合物均有一定的抗肿瘤作用, 其中化合物11a~11c, 11h, 11i对肝癌细胞HepG2的抑制活性优于5-氟尿嘧啶.

关键词: 苦参碱, 呋咱氮氧化合物, NO供体, 抗肿瘤

Abstract: Matrine, one of the major active alkaloids isolated from the Sophora alopecuroides L which is a useful Chinese herbal drug, possesses antipyretic, anti-inflammatory, analgesic, and notable antiviral activities, and has been used for the treatment of lipopolysaccharide-induced liver injury. Recently, it was reported that matrine could inhibit the growth of tumor cells. Nitric oxide(NO), a free radical molecule, is involved in numerous physiological and pathological processes. High levels of NO usually are toxic to tumor cells. It was therefore of interest to determine whether the hybrid of matrine and NO donor furoxan would provide a hitherto unknown class of matrine derivatives that possess potent anticancer activity. Herein furoxan-based matrine compounds 11a—11m were designed and synthesized, and their structures were confirmed by MS, IR, ¹H NMR spectra and elemental analysis. All target compounds exhibited expectedly much more stronger anti human hepatocellular carcinoma cells(HepG2 cells) activity than that of parent compound matrine in vivo. Furthermore, compounds 11a—11c, 11h and 11i had stronger cytotoxic activities than that of control 5-fluorouracil. The concept of designing NO donor-based matrine derivatives that possess potent anticancer activity warrants further investigation.

Key words: Matrine, Furoxan, NO donor, Anti-cancer

TrendMD:

何黎琴, 顾宏霞, 尹登科, 张奕华, 王效山. NO供体型苦参碱衍生物的合成及抗肿瘤活性. 高等学校化学学报, 2010, 31(8): 1541.

HE Li-Qin, GU Hong-Xia, YIN Deng-Ke, ZHANG Yi-Hua*, WANG Xiao-Shan . Synthesis and Anti-cancer Activity of Nitric Oxide Donor-based Matrine Derivatives. Chem. J. Chinese Universities, 2010, 31(8): 1541.

参考文献

[1]ZHAO Bo-Guang(赵博光). Acta Pharmaceutica Sinica(药学学报)[J], 1980, 15(3): 182—183 [2]Cho C. H., Chuang C. Y., Chen C. F.. Planta. Med.[J], 1986, 52(5): 343—345 [3]TAO Shang-Cheng(陶上乘), WANG Jing-Zhen(王静珍). Chinese Pharmaceutical Journal(中国药学杂志)[J], 1992, 27(4): 201—204 [4]AI Jing(艾静), GAO Huan-Huan(高焕焕), HE Shu-Zhuang(何树庄), WANG Ling(王玲), LUO Da-Li(罗大力), YANG Bao-Feng(杨宝峰). Acta Pharmacologica Sinica(中国药理学报)[J], 2001, 22(6): 512—515 [5]ZHANG Jun-Ping(张俊平), ZHANG Min(张珉), ZHOU Jian-Ping(周俭平), LIU Fu-Tang(刘福堂), ZHOU Bin(周斌), XIE Wei-Fen(谢渭芬), GUO Cheng(郭澄), ZHANG Chun(张纯), QIAN Ding-Hua(钱定华). Acta Pharmacologica Sinica(中国药理学报)[J], 2001, 22(2): 183—186 [6]Xu X. R., Jiang J. K.. Chinese Journal of Integrated Traditional and Western Medicine[J], 1998, 4(3): 235—239 [7]YIN Fei(殷飞), ZHAO Jun-Yan(赵军艳), YAO Shu-Kun(姚树坤). Cancer Reseach on Prevention and Treatment(肿瘤防治研究)[J], 2008, 35(2): 84—87 [8]Cheng X. D., Du Y. A., Huang L., Jing Z. M., Zheng Z. G.. Chinese-German Journal of Clinical Oncology[J], 2008, 7(4): 213—216 [9]Hu M. J., Zeng H., Wu Y. L., Zhang Y. P., Zhang S., Qiao M. M., Fu H.. Chin. J. Dig. Dis.[J], 2005, 6(2): 68—71 [10]Chui C. H., Lau F. Y., Tang J. C., Kan K. L., Cheng G. Y., Wong R. S., Kok S. H., Lai P. B., Ho R., Gambari R., Chan A. S.. Int. J. Mol. Med.[J], 2005, 16(2): 337—341 [11]Zhang S. J., Qi J. P., Sun L. B., Cheng B. L., Pan S. H., Zhou M., Sun X. Y.. Mol. Biol. Rep.[J], 2009, 36: 791—799 [12]Zhang Y., Zhang H., Yu P., Liu Q., Liu K., Duan H., Luan G., Yagasaki K., Zhang G.. Cytotechnology[J], 2009, 59(3): 191—200 [13]Tarr J. M., Eggleton P., Winyard P. G.. Curr. Pharm. Des.[J], 2006, 12(34): 4445—4468 [14]Mitra R., Singh S., Khar A.. Expert Rev. Mol. Med.[J], 2003, 5(3): 1—22 [15]Kerwin J. J., Heller M.. Med. Res. Rev.[J], 1994, 14(1): 23—74 [16]Janczuk A. J., Jia Q., Xian M., Wen Z., Wang P. G., Cai T.. Expert Opin. Ther. Pat.[J], 2002, 12(6): 819—826 [17]Rigas B.. Biochem. Soc. Trans.[J], 2007, 35: 1364—1368 [18]Kong X.W., Zhang Y. H., Dai L., Ji H., Lai Y. S., Peng S. X.. Chinese Chemical Letters[J], 2008, 19: 149—152 [19]Moreira D. R., Lima Leite A. C., Pinheiro Ferreira P. M., da Costa P. M., Costa Lotufo L. V., de Moraes M. O., Brondani D. J., Pessoa C. O.. Eur. J. Med. Chem.[J], 2007, 42(3): 351—357